Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Xbrane Biopharma AB ( (SE:XBRANE) ) has shared an update.
Xbrane Biopharma AB has completed a reverse stock split at a ratio of 1:125, consolidating 125 existing shares into one new share, resulting in a total of 20,605,348 shares and votes as of October 31, 2025. This move is part of the company’s strategic financial restructuring, which may impact its stock liquidity and shareholder value, reflecting its ongoing efforts to strengthen its market position.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK11.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology aimed at reducing production costs. The company focuses on biosimilar candidates with a potential market targeting EUR 23 billion in estimated annual peak sales. Their lead product, Ximluci®, has been approved for market authorization in Europe and was launched in 2023. Xbrane is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
YTD Price Performance: -46.76%
Average Trading Volume: 167,943
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK220.5M
Find detailed analytics on XBRANE stock on TipRanks’ Stock Analysis page.